1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBuilding Breakthroughs (Biomanufacturing) is sponsored by Massachusetts Life Sciences Center. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the opportunity page linked on this listing to help you evaluate fit faster.
Building Breakthroughs - MLSC The Building Breakthroughs Capital Call was designed to provide grants for capital projects that support biomanufacturing innovation, including improvements to upstream/downstream processing, production of cell and gene therapies, monoclonal antibodies, and small molecules, quality and safety, and storage/stability, in the Commonwealth.
Up to $10 million capital dollars was available for the previous program round, with approximately $750,000 awarded per project to support work and equipment at not-for-profit partners. Project teams comprised not-for-profit applicants collaborating with at least one for-profit Massachusetts life science company to solve some of the most pressing biomanufacturing problems.
Massachusetts recognizes that as new innovative therapeutic modalities are being developed, including cell and gene therapies, a biomanufacturing bottleneck exists keeping therapies from patients. Further, currently marketed products can benefit from biomanufacturing innovation to reduce costs and avoid drug shortages.
Massachusetts, home to hundreds of companies pioneering innovative therapies and treatments, is well poised to lead in developing these critical biomanufacturing innovations. In May 2019, the MLSC announced $2. 82 million in funding through the Building Breakthroughs capital program.
The capital program funded four projects led respectively by Worcester Polytechnic Institute (WPI), UMass Lowell, and the Massachusetts Institute of Technology (MIT).
Each institution received funding to collaborate with industry stakeholders to take a cross-disciplinary approach to improve the biomanufacturing process for much-needed drugs, therapies, and other treatment pathways for patients around Since 2016, the MLSC has committed more than $21 million to leverage continued investment to accelerate biomanufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading manufacturing Learn more about our 2019 Building Breakthrough awardees, including the principal investigator, industry partners, and project titles.
If you have any questions regarding the application process, e-mail: BuildingBreakthroughs@Masslifesciences. com Business Builds: Life Sciences Transforming Health Care in Massachusetts
According to the current listing, eligibility includes: Entities involved in biomanufacturing innovation in Massachusetts. Confirm the full requirements in the official notice before applying.
Building Breakthroughs (Biomanufacturing) is funded by Massachusetts Life Sciences Center. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Massachusetts. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleAwards slashed by half, life sciences applicants rejected at 95%, and the White House steering which fields get funded. How the GRFP went from funding the person to funding the priority.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read article